MPS Limited has detailed its acquisition of Unbound Medicine, Inc., a US-based leader in healthcare knowledge management, to pivot toward high-growth AI-driven intelligence. Unbound brings a robust subscription-based model with over 90,000 paid subscribers and 1,000+ healthcare facility clients. The acquisition targets a healthcare AI market projected to reach $188 billion by 2030, with a specific subsector CAGR of 42%. MPS plans to leverage its global infrastructure to expand Unbound's reach beyond North America into Europe and APAC, aiming for significant EBITDA uplift.

MPS Limited has scheduled a conference call for February 18, 2026, to provide details on the acquisition of Unbound Medicine, Inc., USA. The acquisition is being executed through its wholly-owned subsidiary, MPS North America LLC. Chairman and CEO Rahul Arora will lead the discussion to explain the strategic rationale and expected synergies. This move highlights the company's ongoing focus on inorganic growth and expansion within the North American market.

MPS Limited, through its US subsidiary MPS North America LLC, has successfully completed the 100% acquisition of Unbound Medicine, Inc., USA. The transaction was finalized for a total consideration of USD 16.50 million following the satisfaction of customary closing conditions. As a result, Unbound Medicine has become a wholly-owned step-down subsidiary of MPS Limited effective February 9, 2026. This acquisition is part of the company's strategy to expand its footprint in the North American market and enhance its digital health and medical education offerings.

MPS Limited reported a steady 9M FY26 performance with revenue reaching INR 563.2 crores, despite a slight dip in Q3 revenue to INR 182.5 crores. The Education Solutions segment showed robust growth of 38% in the first nine months, while Research Solutions remained the anchor with 61.1% revenue contribution. A major highlight is the USD 16.5 million acquisition of Unbound Medicine, a high-margin subscription business in the medical and nursing sector. Management remains confident in surpassing an EPS of INR 100 for FY26, supported by aggressive cost optimization and new synergies.

MPS Limited has outlined a comprehensive funding structure for its USD 16.50 million acquisition of Unbound Medicine, Inc. The acquisition will be financed through a mix of internal accruals, inter-company loans totaling USD 4.94 million, and a new INR 420 million term loan from ICICI Bank. The company is infusing USD 9.81 million as equity into its US subsidiary, MPS North America LLC, to facilitate the transaction. This structured financing ensures the acquisition proceeds without diluting the parent company's 100% stake in its US operations.

MPS Limited reported a strong year-on-year performance for Q3 FY26, with standalone revenue growing 28.2% to ₹111.20 crore compared to ₹86.74 crore in the previous year. Net profit for the quarter stood at ₹28.52 crore, marking a 31.5% increase YoY, despite a marginal 1.8% dip in revenue on a sequential basis. The company also announced the resignation of Non-Executive Director Ms. Yamini Tandon and approved amendments to its Insider Trading Code. Additionally, the board noted the grant of 28,906 ESOPs to eligible employees during the quarter.

MPS Limited reported a resilient performance for Q3 FY26 with revenues of ₹182.5 crore, despite a marginal 2.1% YoY decline. The core Research Solutions segment (excluding AJE) showed strong growth of 16.2% YoY, while Education Solutions grew by 11.3%. The company remains debt-free with a strong cash position of ₹143 crore and is confident of achieving its first-ever annual EPS of ₹100+ for FY26. Profitability in Q3 was impacted by a ₹7.02 crore exceptional provision related to the New Labour Code.

MPS Limited reported a strong performance for Q3 FY26, with revenue from operations growing 23.6% YoY to ₹111.20 crore. Net profit for the quarter increased by 15.5% YoY to ₹28.52 crore, supported by growth across its Content and Learning solutions segments. The company's EPS improved to ₹16.71 from ₹14.47 in the same quarter last year. Additionally, the board noted the resignation of Non-Executive Director Ms. Yamini Tandon and approved amendments to the insider trading code.

MPS Limited, through its US subsidiary, has entered into an agreement to acquire a 100% stake in Unbound Medicine, Inc., a Delaware-based healthcare technology company. Founded in 1999, Unbound Medicine provides digital medical reference and clinical decision-support solutions via a subscription-led institutional model. This acquisition marks MPS's strategic entry into the high-growth healthcare and medical information technology segment. The move aligns with the company's 'Vision 2027' strategy to focus on high-quality, recurring-revenue businesses with strong customer stickiness in the North American market.

MPS Limited, through its US subsidiary, has entered into an agreement to acquire a 100% stake in Unbound Medicine, Inc. for USD 16.50 million in cash. Unbound Medicine is a healthcare learning technology company that reported USD 8.88 million in revenue for CY2024. The acquisition provides MPS entry into the high-growth medical information technology segment and adds over 480 institutional clients to its portfolio. This move is part of MPS's strategic vision to reach INR 1,500 crore in revenue by FY28.